Webinar Series: Clinical Trials in the Era of COVID-19Register Now
Most Recent Articles
In early October, over hundreds of representatives of clinical research sites and members from biopharmaceutical companies came together for WCG’s Global Research Network™ Be the Site of Choice Event.
A forum to gather Patient Advocacy Groups, their constituents, and key stakeholders in drug development to advance and insist upon meaningful change in clinical research.
We are, at last, beginning to better understand the broad range of phenotypic differences in what we classify as autism spectrum disorders.
We asked our network of over 600 experts to share with us what they think makes an expert committee successful.
How can sponsors maximize assay and endpoint sensitivity? And are you meeting scientific and regulatory expectations for quality data in clinical trials?
The placebo effect: it’s the curse of clinical trials across indications. Luckily, training patients to accurately report their symptoms has been proven to reduce placebo response.
On April 25th, NIH Director Francis Collins announced the release of the amended NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules. The most important take-home...
Early phase CNS research is plagued by a higher than average failure rate and complicated by a lack of discreet endpoints. So how can sponsors ameliorate their chances of success from the start?
For the first time in decades, we’re developing CNS drugs with new mechanisms of action. Unfortunately, our measurement tools are stuck in the past.
How can a site move up the selection list and participate in these trials? It’s as simple as one word: metrics.
Adjudication of events of interest can support overall study integrity and ensure reliable, consistent definitions are provided to regulators and the scientific community.
In 2018 WIRB approved 100% of the single-patient EA requests that were submitted for review.